Home LiteratureArticle Details
PMID: 1423820 Published · ppublish English Journal Article Review

The plasminogen-plasmin system in malignancy.

Cancer metastasis reviews ·Vol. 11 ·No. 3-4 ·1992-11-00 ·Pages 291-311

Kwaan HC

Abstract

The study of the plasminogen-plasmin system has, in the past, contributed much to the understanding of fibrinolysis and thrombolysis. Attention is now focused on the role of the components of this system in many biologic functions. Findings of uPA, its receptor and its inhibitor in many tumor tissues and tumor cell lines, strongly implicate their involvement in tumor invasion, tumor cell proliferation and metastasis. The characteristics of the plasminogen activators, the uPA receptor and the plasminogen activator inhibitors as well as their expression and regulation in tumors and tumor cell lines are reviewed.

MeSH Terms
Amino Acid Sequence Animals Fibrinolysin/physiology Humans Molecular Sequence Data Neoplasm Invasiveness Neoplasm Metastasis Neoplasms/blood,enzymology Plasminogen/physiology Plasminogen Activators/physiology Plasminogen Inactivators/physiology
Chemicals
Plasminogen Inactivators Plasminogen Plasminogen Activators Fibrinolysin
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Kwaan H C
Department of Medicine, Northwestern University Medical School, Chicago, IL.
References (229)
229 references, click to expand
  1. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
    Cancer Res. 1985 Apr;45(4):1787-96 PMID: 3884145
  2. Inhibitors of the fibrinolytic enzyme system.
    Semin Thromb Hemost. 1984 Jan;10(1):24-41 PMID: 6199845
  3. Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition.
    Eur J Biochem. 1985 May 15;149(1):193-200 PMID: 3158522
  4. Clotting activation and impairment of fibrinolysis in malignancy.
    Thromb Res. 1989 Jun 15;54(6):699-707 PMID: 2506659
  5. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
    Cancer Res. 1983 Nov;43(11):5517-25 PMID: 6193874
  6. Growth factors in the regulation of plasminogen-plasmin system in tumor cells.
    Semin Thromb Hemost. 1991 Jul;17(3):231-9 PMID: 1839081
  7. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages.
    J Exp Med. 1987 Feb 1;165(2):320-39 PMID: 2434595
  8. Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation.
    J Immunol. 1981 Jul;127(1):179-83 PMID: 7240741
  9. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator.
    N Engl J Med. 1977 May 5;296(18):1017-23 PMID: 66627
  10. Urokinase-type plasminogen activator antigen and early relapse in breast cancer.
    Lancet. 1989 Oct 28;2(8670):1049 PMID: 2572788
  11. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells.
    Cancer Res. 1988 Oct 1;48(19):5539-45 PMID: 3416307
  12. Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
    Carcinogenesis. 1988 Nov;9(11):2121-3 PMID: 3180347
  13. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.
    J Cell Biol. 1988 May;106(5):1659-65 PMID: 2967299
  14. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis.
    Biochemistry. 1987 Jan 27;26(2):338-43 PMID: 3103680
  15. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.
    J Biol Chem. 1986 Aug 25;261(24):11207-13 PMID: 3090045
  16. Proliferation of a human epidermal tumor cell line stimulated by urokinase.
    FASEB J. 1987 Aug;1(2):125-8 PMID: 3038646
  17. Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells.
    Biochim Biophys Acta. 1982 Dec 21;695(2):113-76 PMID: 6763877
  18. Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy.
    Int J Cancer. 1991 Apr 1;47(6):827-32 PMID: 1901298
  19. Enzymatic properties of the phosphorylated urokinase-type plasminogen activator isolated from a human carcinomatous cell line.
    Biochem Biophys Res Commun. 1992 Feb 14;182(3):1473-81 PMID: 1540190
  20. Cancer cell traffic from the lungs to the liver: an example of metastatic inefficiency.
    Int J Cancer. 1980 Mar 15;25(3):385-92 PMID: 7390660
  21. Tumors, mucus production, and hypercoagulability.
    Ann N Y Acad Sci. 1974;230:262-70 PMID: 4522873
  22. Rapid purification of tissue inhibitor of metalloproteinases from human plasma and identification as a gamma-serum protein.
    Biochem J. 1986 Sep 15;238(3):677-82 PMID: 3099772
  23. Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100). Modulation by glucocorticoids.
    J Biol Chem. 1986 Jul 15;261(20):9309-15 PMID: 3087993
  24. Differential protease expression by cutaneous squamous and basal cell carcinomas.
    J Clin Invest. 1991 Oct;88(4):1073-9 PMID: 1918364
  25. Urokinase inhibitor in human placenta.
    Nature. 1968 Jan 20;217(5125):253-4 PMID: 5639129
  26. cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell.
    FEBS Lett. 1987 Jan 1;210(1):11-6 PMID: 3026837
  27. On the lysis of thrombi experimentally produced within veins.
    Br J Haematol. 1958 Jan;4(1):51-62 PMID: 13499833
  28. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
    EMBO J. 1990 Feb;9(2):467-74 PMID: 1689240
  29. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.
    Biochem Biophys Res Commun. 1990 Dec 31;173(3):1058-64 PMID: 2125213
  30. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
    J Urol. 1989 Jul;142(1):193-8 PMID: 2659823
  31. Epidermal growth factor stimulates tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells: mediation by pathways independent of protein kinases-A and -C.
    Endocrinology. 1989 Jul;125(1):126-35 PMID: 2544397
  32. The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors.
    Thromb Res. 1990 May 15;58(4):355-66 PMID: 2112790
  33. Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmic serine protease-binding factor.
    J Cell Physiol. 1983 Nov;117(2):175-82 PMID: 6579053
  34. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
    Cancer Res. 1988 Jun 1;48(11):3112-6 PMID: 2835152
  35. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro.
    Proc Natl Acad Sci U S A. 1974 Apr;71(4):1207-10 PMID: 4208546
  36. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines.
    Cancer Commun. 1991 Aug;3(8):255-64 PMID: 1653586
  37. Chromosomal locations of human tissue plasminogen activator and urokinase genes.
    Science. 1985 Nov 8;230(4726):672-4 PMID: 3840278
  38. Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60.
    Thromb Res. 1988 Jul 15;51(2):175-85 PMID: 3142093
  39. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains.
    Proc Natl Acad Sci U S A. 1984 Sep;81(17):5355-9 PMID: 6089198
  40. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
    EMBO J. 1990 Apr;9(4):1079-85 PMID: 2157592
  41. Increased secretion of plasminogen activator by human macrophages after exposure to leukocyte interferon.
    FEBS Lett. 1981 Jul 6;129(2):233-6 PMID: 6169547
  42. The fibrinolytic enzyme system in malignant lymphomas.
    Acta Haematol. 1973;49(2):89-95 PMID: 4196481
  43. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.
    J Exp Med. 1986 Dec 1;164(6):2113-8 PMID: 3097240
  44. Regulation of the urokinase receptor by its plasminogen activator.
    Thromb Haemost. 1991 Dec 2;66(6):678-83 PMID: 1665597
  45. Tissue plasminogen activator: chemical and physiological aspects.
    Semin Thromb Hemost. 1984 Jan;10(1):6-17 PMID: 6422555
  46. Kringles: modules specialized for protein binding. Homology of the gelatin-binding region of fibronectin with the kringle structures of proteases.
    FEBS Lett. 1984 Jun 4;171(1):131-6 PMID: 6373375
  47. Quantitative determination of the binding of epsilon-aminocaproic acid to native plasminogen.
    J Biol Chem. 1978 Feb 10;253(3):727-32 PMID: 621200
  48. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases.
    Ann Intern Med. 1969 Jul;71(1):67-80 PMID: 5791099
  49. NH2-terminal sequences of mammalian plasminogens and plasmin S-carboxymethyl heavy (A) and light (B) chain derivatives. A re-evaluation of the mechanism of activation of plasminogen.
    J Biol Chem. 1973 Oct 25;248(20):7242-6 PMID: 4270330
  50. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain.
    Hoppe Seylers Z Physiol Chem. 1982 Oct;363(10):1155-65 PMID: 6754569
  51. Linkage disequilibrium of plasminogen polymorphisms and assignment of the gene to human chromosome 6q26-6q27.
    Am J Hum Genet. 1987 Apr;40(4):338-50 PMID: 2883890
  52. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
    Br J Haematol. 1987 May;66(1):85-9 PMID: 3109463
  53. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.
    Blood. 1992 Feb 1;79(3):543-53 PMID: 1732003
  54. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study.
    J Clin Invest. 1969 Sep;48(9):1740-53 PMID: 5822582
  55. Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor.
    Biochemistry. 1991 Jan 29;30(4):979-86 PMID: 1703440
  56. On plasma fibrinolytic activity induced by ischaemia.
    Clin Sci. 1956 May;15(2):245-57 PMID: 13356555
  57. Urokinase plasminogen activator and prognosis in breast cancer.
    Lancet. 1990 Jan 13;335(8681):108 PMID: 1967386
  58. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3.
    J Biol Chem. 1987 Nov 25;262(33):15813-6 PMID: 2824468
  59. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration.
    Mol Cell Biol. 1986 Nov;6(11):4060-6 PMID: 3025628
  60. Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human hemopoietic cells.
    J Exp Med. 1987 Jun 1;165(6):1609-23 PMID: 3108448
  61. Fibrinolytic activity in malignant disease.
    J Clin Pathol. 1975 Nov;28(11):872-4 PMID: 1236626
  62. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol.
    J Biol Chem. 1991 Jan 25;266(3):1926-33 PMID: 1846368
  63. The fibrinolytic enzyme system in prostatic cancer.
    Cancer. 1959 Jul-Aug;12(4):721-30 PMID: 13663015
  64. Phosphorylation of a surface receptor bound urokinase-type plasminogen activator in a human metastatic carcinomatous cell line.
    Biochem Biophys Res Commun. 1992 Feb 14;182(3):1466-72 PMID: 1311574
  65. Cell-associated plasminogen activation: regulation and physiological functions.
    Annu Rev Cell Biol. 1988;4:93-126 PMID: 3143380
  66. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen.
    Biochim Biophys Acta. 1979 Jul 25;579(1):142-54 PMID: 157166
  67. The cell-binding domains of plasminogen and their function in plasma.
    J Biol Chem. 1988 Aug 25;263(24):11928-34 PMID: 3403557
  68. The secretion of plasminogen activators by human myeloid leukemic cells in vitro.
    Blood. 1983 Mar;61(3):568-74 PMID: 6572078
  69. Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562).
    Blood. 1989 Sep;74(4):1321-7 PMID: 2504306
  70. Secretion of plasminogen activator by bone marrow-derived mononuclear phagocytes and its enhancement by colony-stimulating factor.
    J Exp Med. 1979 Aug 1;150(2):231-45 PMID: 313429
  71. Components of the plasminogen-plasmin system in human tumor cell lines.
    Semin Thromb Hemost. 1991 Jul;17(3):175-82 PMID: 1839079
  72. The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants.
    J Cell Biol. 1985 Nov;101(5 Pt 1):1790-8 PMID: 2997235
  73. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.
    J Clin Invest. 1986 Dec;78(6):1673-80 PMID: 3097076
  74. Growth factors in the regulation of pericellular proteolysis: a review.
    Cancer Res. 1989 May 15;49(10):2533-53 PMID: 2469534
  75. Integrins: a family of cell surface receptors.
    Cell. 1987 Feb 27;48(4):549-54 PMID: 3028640
  76. Blood coagulation and fibrinolysis in tissue culture and tissue repair.
    Biochem Pharmacol. 1968 Mar;:Suppl:241-57 PMID: 4870938
  77. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.
    J Lab Clin Med. 1985 Jun;105(6):751-8 PMID: 2987382
  78. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule.
    N Engl J Med. 1978 Aug 3;299(5):221-6 PMID: 207986
  79. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin.
    J Biol Chem. 1967 May 25;242(10):2333-42 PMID: 4226004
  80. Human monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment, and homology to plasminogen activator-inhibitor.
    J Exp Med. 1987 Jul 1;166(1):77-94 PMID: 3496414
  81. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
    Science. 1986 Sep 19;233(4770):1318-21 PMID: 3489291
  82. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor.
    Eur J Clin Invest. 1985 Dec;15(6):308-12 PMID: 3938400
  83. The plasminogen-plasmin system.
    Prog Cardiovasc Dis. 1991 Sep-Oct;34(2):135-64 PMID: 1832499
  84. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
    Cancer Res. 1990 Nov 1;50(21):6827-9 PMID: 2119883
  85. On the production of plasma fibrinolytic activity within veins.
    Clin Sci. 1957 May;16(2):241-53 PMID: 13427182
  86. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos.
    J Cell Biol. 1989 Nov;109(5):2471-9 PMID: 2509486
  87. Alveolar epithelial cell plasminogen activator. Characterization and regulation.
    J Biol Chem. 1990 May 15;265(14):8198-204 PMID: 2110565
  88. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator.
    Semin Thromb Hemost. 1991 Jul;17(3):183-93 PMID: 1665583
  89. Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons.
    Proc Natl Acad Sci U S A. 1987 Aug;84(15):5459-63 PMID: 3474662
  90. Cellular regulation of fibrinolysis.
    Thromb Haemost. 1991 Jul 12;66(1):32-6 PMID: 1656542
  91. Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue.
    Thromb Haemost. 1982 Aug 24;48(1):24-6 PMID: 6813991
  92. Plasminogen activator inhibitor in stomach and colorectal carcinomas.
    Semin Thromb Hemost. 1991 Jul;17(3):276-9 PMID: 1796298
  93. Some epidemiologic considerations of thromboembolism.
    Surg Gynecol Obstet. 1959 Oct;109:487-501 PMID: 13811753
  94. The relevance of plasminogen activators to neoplastic growth. A review of recent literature.
    Enzyme. 1988;40(2-3):158-72 PMID: 3049065
  95. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.
    J Cell Biol. 1987 Aug;105(2):957-63 PMID: 3114269
  96. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins.
    J Biol Chem. 1976 Sep 25;251(18):5694-702 PMID: 965386
  97. Dysplasminogenemias.
    Prog Cardiovasc Dis. 1992 Jan-Feb;34(4):295-308 PMID: 1530828
  98. Locally acting growth factors for vascular smooth muscle cells: endogenous synthesis and release from platelets.
    Circulation. 1985 Oct;72(4):735-40 PMID: 3896561
  99. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.
    J Biol Chem. 1987 Apr 5;262(10):4437-40 PMID: 3031025
  100. Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta.
    J Cell Biol. 1988 Feb;106(2):451-9 PMID: 3276718
  101. Thrombospondin: a versatile multifunctional glycoprotein.
    Arteriosclerosis. 1986 May-Jun;6(3):245-53 PMID: 3518684
  102. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
    J Clin Invest. 1985 Mar;75(3):818-24 PMID: 3920245
  103. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells.
    Cell. 1980 Aug;21(1):37-45 PMID: 6157479
  104. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils.
    Biochem Biophys Res Commun. 1987 Sep 30;147(3):1176-81 PMID: 3117059
  105. Fibrinolysis and cancer.
    Semin Thromb Hemost. 1990 Jul;16(3):230-5 PMID: 2146746
  106. A pattern of epidermal cell migration during wound healing.
    J Cell Biol. 1971 May 1;49(2):247-63 PMID: 19866757
  107. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery.
    Circ Res. 1990 Jul;67(1):61-7 PMID: 2114227
  108. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
    Proc Natl Acad Sci U S A. 1989 Jul;86(14):5424-8 PMID: 2501786
  109. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
    J Biol Chem. 1986 Jun 15;261(17):7644-51 PMID: 3086313
  110. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration.
    Proc Natl Acad Sci U S A. 1986 Apr;83(7):2091-5 PMID: 3008151
  111. Antimetastatic effect of amiloride in an animal tumour model.
    Anticancer Res. 1988 Nov-Dec;8(6):1373-6 PMID: 3218971
  112. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
    Invasion Metastasis. 1985;5(6):344-55 PMID: 4066206
  113. Hormone regulation of tissue-type plasminogen activator gene expression and plasminogen activator-mediated proteolysis.
    Semin Thromb Hemost. 1991 Jul;17(3):286-90 PMID: 1796299
  114. Increased plasminogen activator inhibition levels in malignancy.
    Thromb Haemost. 1987 Apr 7;57(2):140-3 PMID: 3110994
  115. The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human acute myeloid leukemia cells.
    Blood. 1983 Mar;61(3):561-7 PMID: 6572077
  116. The isolation and characterization of plasminogen activators (urokinase) from human urine.
    Biochemistry. 1966 Jul;5(7):2160-9 PMID: 4959959
  117. Tissue-type plasminogen activator, a new prognostic marker in breast cancer.
    Cancer Res. 1988 Mar 1;48(5):1348-9 PMID: 3124957
  118. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
    Cancer Res. 1987 Sep 1;47(17):4654-7 PMID: 3621160
  119. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.
    J Biol Chem. 1991 Jul 5;266(19):12752-8 PMID: 1829461
  120. Proteolytic degradation of extracellular matrix in tumor invasion.
    Biochim Biophys Acta. 1987 Nov 25;907(3):191-217 PMID: 2823896
  121. Plasminogen activator in the bursa of Fabricius: correlations with morphogenetic remodeling and cell migrations.
    Cell. 1981 Aug;25(2):471-6 PMID: 7197195
  122. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.
    Blood. 1992 Mar 15;79(6):1447-55 PMID: 1312369
  123. Impaired fibrinolysis-inducing capacity for postinjury phenotype of cultivated human arterial and human atherosclerotic intimal smooth muscle cells.
    Circ Res. 1988 May;62(5):1011-8 PMID: 3359571
  124. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
    Thromb Haemost. 1986 Aug 20;56(1):1-5 PMID: 3095944
  125. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination.
    Br J Haematol. 1989 Apr;71(4):511-7 PMID: 2496742
  126. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
    Am J Pathol. 1991 May;138(5):1059-67 PMID: 1850957
  127. Plasma antithrombin patterns in disturbances of the pancreas.
    Gastroenterology. 1951 Dec;19(4):843-54 PMID: 14897078
  128. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
    Exp Cell Res. 1991 Feb;192(2):453-9 PMID: 1899072
  129. Plasminogen activation by receptor-bound urokinase.
    Semin Thromb Hemost. 1991 Jul;17(3):194-200 PMID: 1665584
  130. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.
    Blood. 1984 Oct;64(4):907-13 PMID: 6434006
  131. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.
    J Cell Biol. 1987 Mar;104(3):705-12 PMID: 3102504
  132. Plasminogen activator as a prognostic factor in hematological malignancies.
    Haematol Blood Transfus. 1985;29:197-9 PMID: 3861481
  133. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Thromb Res. 1987 Aug 15;47(4):459-68 PMID: 2821651
  134. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts.
    Lab Invest. 1989 Jul;61(1):20-6 PMID: 2473276
  135. EPITHELIALIZATION OF SMALL WOUNDS.
    J Invest Dermatol. 1964 Dec;43:499-507 PMID: 14234856
  136. Inhibitors of fibrinolysis in platelets in polycythaemia vera and thrombocytosis.
    Br J Haematol. 1971 Sep;21(3):313-22 PMID: 4255014
  137. Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma, U138.
    Biochem Cell Biol. 1988 Dec;66(12):1270-7 PMID: 3149898
  138. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
    J Biol Chem. 1990 Jun 15;265(17):9904-8 PMID: 2161846
  139. Plasminogen activator and proactivator (urokinase precursor) in lung cultures.
    J Am Med Womens Assoc (1972). 1976 Dec;31(12):465-72 PMID: 186502
  140. The biology of cancer invasion and metastasis.
    Adv Cancer Res. 1978;28:149-250 PMID: 360795
  141. Mouse neural crest cells secrete both urokinase-type and tissue-type plasminogen activators in vitro.
    Development. 1989 Aug;106(4):685-90 PMID: 2562663
  142. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.
    Br J Haematol. 1986 Feb;62(2):221-8 PMID: 3484964
  143. Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue.
    Biochim Biophys Acta. 1984 Feb 14;797(2):256-65 PMID: 6199043
  144. Thrombospondin, a potentiator of tumor cell metastasis.
    Cancer Res. 1987 Aug 1;47(15):4130-3 PMID: 3607754
  145. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Cancer Res. 1984 May;44(5):1946-53 PMID: 6608989
  146. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme.
    Eur J Biochem. 1989 Apr 15;181(1):103-7 PMID: 2540964
  147. Tissue-type plasminogen activator in patients with intracranial meningiomas.
    Thromb Haemost. 1988 Dec 22;60(3):508-13 PMID: 3149049
  148. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis.
    Int J Cancer. 1982 Nov 15;30(5):669-73 PMID: 6295970
  149. The role of proteinases in cellular invasiveness.
    Biochim Biophys Acta. 1983 Dec 29;695(3-4):177-214 PMID: 6317025
  150. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.
    Proc Natl Acad Sci U S A. 1986 Sep;83(18):6776-80 PMID: 3092219
  151. Expression of urokinase-type plasminogen activator by rat pulmonary alveolar epithelial cells.
    Am J Respir Cell Mol Biol. 1990 Nov;3(5):449-56 PMID: 2121171
  152. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
    Cancer. 1988 Aug 1;62(3):531-3 PMID: 3134120
  153. Tissue plasminogen activators in breast cancer.
    Thromb Res. 1987 Mar 1;45(5):601-7 PMID: 3109062
  154. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA.
    Biochemistry. 1986 Apr 22;25(8):2220-5 PMID: 3011081
  155. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
    J Cell Biol. 1985 Jan;100(1):86-92 PMID: 3880760
  156. Origin of fibrinolytic activity in cultures of the human kidney.
    J Lab Clin Med. 1967 Oct;70(4):650-61 PMID: 6052965
  157. Tissue plasminogen activator activity in prostatic cancer.
    Eur Urol. 1984;10(6):389-94 PMID: 6085049
  158. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.
    J Biol Chem. 1986 Mar 15;261(8):3486-9 PMID: 3081506
  159. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.
    J Cell Biol. 1987 Dec;105(6 Pt 1):2543-9 PMID: 3121634
  160. Coagulation disorders in cancer. I. Clinical and laboratory studies.
    Cancer. 1967 Sep;20(9):1452-65 PMID: 6038391
  161. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.
    Thromb Res. 1984 Mar 1;33(5):523-30 PMID: 6426082
  162. Plasminogen activators, tissue degradation, and cancer.
    Adv Cancer Res. 1985;44:139-266 PMID: 2930999
  163. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
    Blood. 1991 May 1;77(9):1949-57 PMID: 1708294
  164. Studies on the release of a plasminogen activator inhibitor by human platelets.
    Thromb Haemost. 1986 Apr 30;55(2):201-5 PMID: 2940723
  165. Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.
    Cancer Res. 1989 Feb 15;49(4):816-20 PMID: 2912554
  166. Regulation of plasminogen activator production by cultured endothelial cells.
    Ann N Y Acad Sci. 1982;401:184-94 PMID: 6963120
  167. Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors.
    Leuk Res. 1988;12(5):419-22 PMID: 3379974
  168. Correlation of hyperfibrinogenemia with major thromboembolism in patients with cancer.
    Surg Gynecol Obstet. 1973 Jan;136(1):75-7 PMID: 4682267
  169. Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells.
    Mol Cell Biol. 1987 Dec;7(12):4564-7 PMID: 3325828
  170. Activation of plasminogen by pro-urokinase. I. Mechanism.
    J Biol Chem. 1986 Jan 25;261(3):1253-8 PMID: 2935528
  171. Antibodies to plasminogen activator inhibit human tumor metastasis.
    Cell. 1983 Dec;35(3 Pt 2):611-9 PMID: 6418388
  172. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood.
    Thromb Haemost. 1986 Jun 30;55(3):325-9 PMID: 3092389
  173. New perspectives in cell adhesion: RGD and integrins.
    Science. 1987 Oct 23;238(4826):491-7 PMID: 2821619
  174. Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator.
    Int J Cancer. 1981 Oct 15;28(4):509-15 PMID: 6273336
  175. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells.
    J Exp Med. 1986 May 1;163(5):1260-6 PMID: 3084701
  176. Antifibrinolytic activity in primary carcinoma of the liver.
    Clin Sci. 1959 May;18:251-61 PMID: 14413062
  177. Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells.
    Int J Cancer. 1989 May 15;43(5):816-22 PMID: 2497073
  178. Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2.
    EMBO J. 1989 Nov;8(11):3287-94 PMID: 2583099
  179. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system.
    J Cell Biol. 1990 Aug;111(2):757-63 PMID: 1696270
  180. Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of natural killer cell-mediated cytotoxicity.
    Int J Cancer. 1980 Nov 15;26(5):675-80 PMID: 6972360
  181. Two-color cytofluorometry and cellular properties of the urokinase receptor associated with a human metastatic carcinomatous cell line.
    Exp Cell Res. 1991 Feb;192(2):405-13 PMID: 1846335
  182. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
    J Cell Biol. 1989 May;108(5):1987-95 PMID: 2523891
  183. Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan.
    J Cell Biol. 1991 Sep;114(6):1275-83 PMID: 1654337
  184. Plasminogen activator activity is associated with neural crest cell motility in tissue culture.
    J Exp Zool. 1989 Aug;251(2):123-33 PMID: 2549170
  185. Structure-function mapping of interleukin 1 precursors. Cleavage leads to a conformational change in the mature protein.
    J Biol Chem. 1991 Apr 15;266(11):7081-6 PMID: 2016316
  186. Thrombophlebitis in cancer patients.
    Ann N Y Acad Sci. 1981;370:138-44 PMID: 6943957
  187. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
    Semin Thromb Hemost. 1991 Jul;17(3):303-12 PMID: 1796300
  188. Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters.
    J Biol Chem. 1990 Jan 25;265(3):1333-8 PMID: 2153128
  189. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.
    J Cell Biol. 1989 Feb;108(2):693-702 PMID: 2537321
  190. Type-1 plasminogen activator inhibitor in human breast carcinomas.
    Int J Cancer. 1992 Jan 21;50(2):208-14 PMID: 1730515
  191. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
    Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939-43 PMID: 2991901
  192. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.
    J Biol Chem. 1988 Apr 25;263(12):5797-803 PMID: 3128548
  193. Plasminogen activation and regulation of pericellular proteolysis.
    Biochim Biophys Acta. 1985 Nov 12;823(1):35-65 PMID: 2413894
  194. Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptor.
    Semin Thromb Hemost. 1991 Jul;17(3):225-30 PMID: 1665585
  195. Genetic polymorphism of human plasminogen.
    Am J Hum Genet. 1980 Sep;32(5):681-9 PMID: 7424908
  196. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.
    Mol Cell Biol. 1989 May;9(5):2133-41 PMID: 2747645
  197. Enhanced activation of prourokinase by human RC2A leukemia cells.
    Semin Thromb Hemost. 1991 Jul;17(3):251-61 PMID: 1665587
  198. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system.
    J Biol Chem. 1990 Apr 15;265(11):6104-11 PMID: 2318848
  199. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
    Cancer Res. 1988 Mar 1;48(5):1270-8 PMID: 2963689
  200. Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies.
    Adv Cancer Res. 1985;43:1-73 PMID: 2581423
  201. Plasminogen activator inhibitor in the blood of patients with coronary artery disease.
    Br Med J (Clin Res Ed). 1985 Aug 31;291(6495):573-4 PMID: 3929877
  202. Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity: paradoxical induction of both tPA antigen and plasminogen activator inhibitor.
    Mol Endocrinol. 1987 Jan;1(1):97-101 PMID: 3137452
  203. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.
    Cancer Res. 1989 Nov 1;49(21):6064-9 PMID: 2551498
  204. Epidermal growth factor and 12-tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells.
    Semin Thromb Hemost. 1991 Jul;17(3):217-24 PMID: 1796295
  205. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine.
    Arch Biochem Biophys. 1983 Jan;220(1):31-8 PMID: 6338833
  206. The production of plasma fibrinolytic activity in vivo by serotonin (5-hydroxytryptamine) creatinine sulphate.
    Clin Sci. 1957 May;16(2):255-9 PMID: 13427183
  207. Plasminogen activator profiles in neoplastic tissues of the human colon.
    Cancer Res. 1988 Aug 15;48(16):4520-4 PMID: 3260815
  208. Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level.
    Biochem Soc Trans. 1991 Feb;19(1):44S PMID: 1903741
  209. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.
    EMBO J. 1986 Oct;5(10):2539-44 PMID: 2430793
  210. Structural characterization and biological functions of fibroblast growth factor.
    Endocr Rev. 1987 May;8(2):95-114 PMID: 2440668
  211. Binding site of alpha 2-plasmin inhibitor to plasminogen.
    Biochim Biophys Acta. 1988 Jan 4;952(1):1-7 PMID: 3334852
  212. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
    Cancer Res. 1980 Mar;40(3):841-8 PMID: 7193515
  213. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
    Blood. 1990 May 15;75(10):1991-8 PMID: 2140060
  214. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.
    J Urol. 1988 Dec;140(6):1466-9 PMID: 3193516
  215. Inhibitors of fibrinolysis in human tissues in culture.
    Am J Physiol. 1971 Sep;221(3):916-21 PMID: 4255082
  216. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.
    Biochim Biophys Acta. 1975 May 30;393(1):55-65 PMID: 124594
  217. Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies.
    Am J Obstet Gynecol. 1984 Aug 15;149(8):830-4 PMID: 6540521
  218. The fibrin-binding site of human plasminogen. Arginines 32 and 34 are essential for fibrin affinity of the kringle 1 domain.
    J Biol Chem. 1984 Nov 25;259(22):13690-4 PMID: 6094526
  219. A classification of disorders of hemostasis and thrombosis in patients with malignancy.
    Prog Clin Biol Res. 1982;89:1-20 PMID: 7111293
  220. Fibronectin and its receptors.
    Annu Rev Biochem. 1988;57:375-413 PMID: 2972252
  221. Hemostasis in malignancy.
    Ann N Y Acad Sci. 1974;230:252-61 PMID: 4522872
  222. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase.
    Proc Natl Acad Sci U S A. 1989 Apr;86(8):2632-6 PMID: 2468156
  223. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
    Cell Differ Dev. 1990 Dec 2;32(3):287-92 PMID: 1711915
  224. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.
    J Biol Chem. 1988 Feb 15;263(5):2358-63 PMID: 2828365
  225. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
    J Cell Biol. 1987 Apr;104(4):1085-96 PMID: 3104349
  226. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
    Cancer Metastasis Rev. 1990 Dec;9(4):353-67 PMID: 2129023
  227. cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta.
    J Biol Chem. 1987 Mar 15;262(8):3718-25 PMID: 3029122
  228. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
    Prostate. 1991;18(3):201-14 PMID: 1902292
  229. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes.
    J Biol Chem. 1989 Feb 5;264(4):2185-8 PMID: 2521625
Article Info
Journal
Cancer metastasis reviews
Abbr.
Cancer Metastasis Rev
ISSN
0167-7659
DOI
10.1007/BF01307184
Published
1992-11-00
Pages
291-311
Language
English
Region
Netherlands
NLM ID
8605731
Subset
IM
External Links
PubMed source DOI: 10.1007/BF01307184 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2